Halozyme CEO Executes 10b5-1 Plan, Sells 60,000 Shares After Exercise

Rhea-AI Filing Summary

Helen Torley, President and CEO and a director of Halozyme Therapeutics (HALO), exercised a total of 60,000 stock options at an $8.11 exercise price and concurrently sold the resulting 60,000 common shares over three days. The sales were executed at weighted-average prices reported in ranges between $62.54 and $64.96 per share, and the Form reports 733,719 shares beneficially owned by the reporting person following these transactions.

The filings state the transactions were made under a written Rule 10b5-1 trading plan adopted March 21, 2025, and that the sold shares were acquired upon exercise of options with ten-year terms expiring in February 2026. The underlying options were originally granted February 3, 2016, with a four-year vesting schedule.

Positive

• Trades executed under a Rule 10b5-1 plan, indicating pre-established, documented trading intent
• Reporting person retains substantial ownership with 733,719 shares beneficially owned after the transactions

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider exercised and sold 60,000 shares under a pre-established plan; remaining ownership remains sizable at 733,719 shares.

The reporting shows sequential exercises of 20,000 options on each of three days at an $8.11 strike, immediately followed by sales of the same 20,000-share blocks at weighted-average prices within the $62.54–$64.96 range. Net effect: the CEO realized proceeds from option exercise and sale while ending with 733,719 shares beneficially owned. Transactions were executed under a documented 10b5-1 plan, which typically reduces the likelihood of opportunistic timing concerns. Overall, the activity is routine and not immediately material to Halozyme’s capital structure.

Corporate Governance Expert

TL;DR: Trades were pre-planned under a Rule 10b5-1 plan; disclosure is complete and includes price ranges and option grant details.

The Form discloses that the sales were made pursuant to a written trading plan adopted March 21, 2025, and that the shares sold derived from option exercises of grants dated February 3, 2016. The filing includes explicit weighted-average price ranges for each sale block and shows post-transaction beneficial ownership of 733,719 shares. From a governance perspective, the documentation and level of disclosure align with standard compliance practices for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	08/11/2025		S(1)		18,717	D	$63.008(2)	735,002	D
Common Stock	08/11/2025		S(1)		1,283	D	$63.598(3)	733,719	D
Common Stock	08/12/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	08/12/2025		S(1)		13,042	D	$63.242(4)	740,677	D
Common Stock	08/12/2025		S(1)		6,958	D	$64.001(5)	733,719	D
Common Stock	08/13/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	08/13/2025		S(1)		14,948	D	$64.145(6)	738,771	D
Common Stock	08/13/2025		S(1)		5,052	D	$64.828(7)	733,719	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$8.11	08/11/2025		M(1)			20,000	(8)	02/03/2026	Common Stock	20,000	$8.11	236,569	D
Option to Purchase Common Stock	$8.11	08/12/2025		M(1)			20,000	(8)	02/03/2026	Common Stock	20,000	$8.11	216,569	D
Option to Purchase Common Stock	$8.11	08/13/2025		M(1)			20,000	(8)	02/03/2026	Common Stock	20,000	$8.11	196,569	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.54 to $63.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.54 to $63.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.68 to $63.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.745 to $64.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.70 to $64.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.70 to $64.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.

	/s/ James R. Oehler, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who reported the insider transactions for HALO?

Helen Torley, President and CEO and a director of Halozyme Therapeutics, is the reporting person.

How many options were exercised and at what strike price?

A total of 60,000 options were exercised at a strike price of $8.11 per share.

How many shares were sold and at what prices?

60,000 common shares were sold over three days at weighted-average prices within reported ranges from $62.54 to $64.96 per share.

Were the sales part of a 10b5-1 trading plan?

Yes. The Form states the transactions were made pursuant to a written Rule 10b5-1 plan adopted March 21, 2025.

What is the reporting person's ownership after these transactions?

The filing reports 733,719 shares beneficially owned following the reported transactions.